IMIS | Flanders Marine Institute
 

Flanders Marine Institute

Platform for marine research

IMIS

Publications | Institutes | Persons | Datasets | Projects | Maps
[ report an error in this record ]basket (0): add | show Printer-friendly version

Natural Products as Sources of New Drugs over the Period 1981-2002
Newman, D.J.; Cragg, G.M.; Snader, K.M. (2003). Natural Products as Sources of New Drugs over the Period 1981-2002. J. Nat. Prod. 66(7): 1022-1037
In: Journal of Natural Products. American Chemical Society/American Society of Pharmacognosy: Washington, DC, etc.. ISSN 0163-3864, more
Peer reviewed article  

Available in Authors 

Keyword
    Marine

Authors  Top 
  • Newman, D.J.
  • Cragg, G.M.
  • Snader, K.M.

Abstract
    This review is an updated and expanded version of a paper that was published in this journal in 1997. The time frame has been extended in both directions to include the 22 years from 1981 to 2002, and a new secondary subdivision related to the natural product source but applied to formally synthetic compounds has been introduced, using the concept of a “natural product mimic” or “NM” to join the original primary divisions. From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well. Thus, in the area of cancer, the percentage of small molecule, new chemical entities that are nonsynthetic has remained at 62% averaged over the whole time frame. In other areas, the influence of natural product structures is quite marked, particularly in the antihypertensive area, where of the 74 formally synthetic drugs, 48 can be traced to natural product structures/mimics. Similarly, with the 10 antimigraine drugs, seven are based on the serotonin molecule or derivatives thereof. Finally, although combinatorial techniques have succeeded as methods of optimizing structures and have, in fact, been used in the optimization of a number of recently approved agents, we have not been able to identify a de novo combinatorial compound approved as a drug in this time frame.

All data in IMIS is subject to the VLIZ privacy policy Top | Authors